Welcome to this exclusive OncologyTube.com companion to our video, “Comprehensive Overview of Bispecific Antibodies in Cancer Therapy.” Bispecific antibodies (bsAbs)…
Browsing: Multiple Myeloma
This video presents the myeloma treatment algorithm 2025 for transplant-ineligible patients, shared by Dr. Vincent Rajkumar at ASCO 2025. Designed…
Author: Dr. Zandra Klippel, Global Product Head, Multiple Myeloma, Sanofi At the ASCO 2024 conference, Dr. Zandra Klippel the Global…
… Multiple myeloma, an incurable cancer affecting plasma cells in the bone marrow, continues to challenge the medical community. The…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
ASH Groundbreaking Trials and Therapies Transform Multiple Myeloma Treatment The recent American Society of Hematology (ASH) meeting showcased significant advancements…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
The battle against polycythemia vera (PV), a rare and chronic form of blood cancer, has seen a transformative advancement with…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews Below) On February 20th, 2024…
Al-Ola Abdallah, MD, Associate Professor of Medicine at The University of Kansas, conducted a study titled Outcomes of Vdpace for…
Asya Nina Varshavsky-Yanovsky, MD, PhD, serves as an Assistant Professor within the Department of Bone Marrow Transplant and Cellular Therapies.…
At ASH 2023, Hamza Hashmi, MD, a medical doctor and hematologist from Charleston, South Carolina, discussed a multicenter study focusing…
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab) + KRd significantly improved rate…
At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at the Sylvester Comprehensive Cancer Center,…
By. Robert Rifkin, MDDate: 12/13/2023 Robert Rifkin, MD, a medical oncologist and hematologist at SCRI in Rocky Mountain Cancer Centers,…
By. Katja Weisel, MD Date: October 25. 2023 In the world of multiple myeloma research, Dr. Katja Weisel, MD, stands…
KEY TAKEAWAYS Bispecific antibodies, such as talquetamab, represent a transformative shift in cancer treatment, offering the potential to target two…
Refractory multiple myeloma remains a significant challenge in the field of oncology, necessitating innovative therapeutic strategies. Mezigdomide, a novel oral…
Majid Jaberi-Douraki, PhD from Kansas State University, and Shahzad Raza, MD from the Cleveland Clinic, conducted a study to evaluate…
Majid Jaberi-Douraki, PhD -Kansas State University and Shahzad Raza, MD – Cleveland Clinic This study analyzed data from the FDA…
by: Niels Van de Donk, MD, Amsterdam UMC Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, continues to show…
Monique Hartley-Brown, MD, MMSc, from Dana-Farber Cancer Institute, conducted a significant clinical study called “SUCCESSOR-2” that focused on the treatment…
“Correction: The mPFS is not 34 months but 34%.” Carolina Schinke, MD from the UASM Health provided insights into the…
In this study, the researchers evaluated the use of standard of care (SOC) ciltacabtagene autoleucel in a patient population and…
Idecabtagene Vicleucel Shows Effectiveness and Safety in High-Risk Multiple Myeloma Patients Krina Patel MD By Krina Patel, MD, MSc So…
REGN5458: A Trial for Relapsed/Refractory Multiple Myeloma a BCMAxCD3 Bispecific Antibody Naresh Bumma MD By Naresh Bumma, MD – Ohio…
2023 ASH BCMA & Multiple Myeloma Updates with Slides by: Lisa Lee, MD – Assistant Professor — Division of Hematology-Oncology, Department…
What ASH abstracts stood out to you most in multiple myeloma? By Lisa X. Lee, MD from UCI Health At…
MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with…
iFrame is not supported! MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP…
MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with…
Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated…
Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated…
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How…
iFrame is not supported! Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is…
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How…
MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do…
iFrame is not supported! MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can…
MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do…
GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with…
iFrame is not supported! GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can…
GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with…
TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from…
iFrame is not supported! Idecabtagene: ASH 2022 Multiple Myeloma Madhav Dhodapkar KarMMa-2 By Madhav Dhodapkar, MBBS What is Idecabtagene, and…
Idecabtagene: ASH 2022 Multiple Myeloma Madhav Dhodapkar KarMMa-2 By Madhav Dhodapkar, MBBS What is Idecabtagene, and how can it help…
iFrame is not supported! Isatuximab: ASH 2022 Multiple Myeloma Paul Richardson ICARIA By Paul Richardson, MD What can Pomalidomide/Dexamethasone do…
Isatuximab: ASH 2022 Multiple Myeloma Paul Richardson ICARIA By Paul Richardson, MD What can Pomalidomide/Dexamethasone do for Relapsed/Refractory Multiple Myeloma…
iFrame is not supported! Car- T DDBMCA By Matthew Frigault, MD Car T cell DDBMCA is a autologous chimeric enogen…
iFrame is not supported! Car- T DDBMCA By Matthew Frigault, MD Car T cell DDBMCA is a autologous chimeric enogen…
iFrame is not supported! Mezigdomnide Preliminary Results Multiple Myeloma from the Dose-Expansion Phase of the CC-92480-MM-001 By Paul Richardson, MD…
Mezigdomnide Preliminary Results Multiple Myeloma from the Dose-Expansion Phase of the CC-92480-MM-001 By Paul Richardson, MD How can Mezigdomide (CC-92480)…
iFrame is not supported! Daratumumab: COVID-19 Impact – Robert Rifkin – ASH 2022 By Robert Rifkin, MD What is the…
Daratumumab: COVID-19 Impact – Robert Rifkin – ASH 2022 By Robert Rifkin, MD What is the Connect® MM Registry and…
This immersive practice guide offers “how to†methods and day-to-day strategies via faculty commentary and a review of data and…
The MM6 trial marks a significant advancement in multiple myeloma treatment, specifically for relapsed or refractory multiple myeloma (RRMM). For…
The GRIFFIN Study is a post-hoc analysis of sustained MRD negative status in the griffin study which treated patients with…
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, Haematologist with clinical and research interests in multiple myeloma, in particular myeloma, lymphoma…
The study that I will be discussing today is the frailty subgroup analysis of the CANDOR study, which is a…
Michael B. Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, William M. Scholl Professor and Vice-Chair Department of Oncology and…
Michael B. Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, William M. Scholl Professor and Vice-Chair Department of Oncology and…
Matthew J. Frigault, MD, Clinical Director- Cellular Immunotherapy Program at Mass General Cancer Center. In this video, he speaks about…
Matthew J. Frigault, MD, Clinical Director- Cellular Immunotherapy Program at Mass General Cancer Center. In this video, he speaks about…
Doris Hansen, MD, Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy at…
Doris Hansen, MD, Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy at…
Jens Hillengass, MD, Ph.D., Chief of Myeloma, Professor of Oncology at Roswell Park Comprehensive Cancer Center. In this video, he…
Jens Hillengass, MD, Ph.D., Chief of Myeloma, Professor of Oncology at Roswell Park Comprehensive Cancer Center. In this video, he…
Dr. Timothy Schmidt from the Carbone Cancer Center, and the University of Wisconsin, is a faculty member of the Division…
Dr. Timothy Schmidt from the Carbone Cancer Center, and the University of Wisconsin, is a faculty member of the Division…
Philippe Moreau, MD, is Head of the Hematology Department at the University Hospital of Nantes, France speaks about the ASH…
Philippe Moreau, MD, is Head of the Hematology Department at the University Hospital of Nantes, France speaks about the ASH…
Saad Z. Usmani, MD MBA FACP, Chief, Myeloma Service at Memorial Sloan Kettering Cancer Center speaks about New Data from…
Saad Z. Usmani, MD MBA FACP, Chief, Myeloma Service at Memorial Sloan Kettering Cancer Center speaks about New Data from…
Jacob Laubach, MD, MPP from the Dana-Farber Cancer Institute speaks about the ASH 2021 Abstract – 79 Daratumumab (DARA) Plus…
Jacob Laubach, MD, MPP from the Dana-Farber Cancer Institute speaks about the ASH 2021 Abstract – 79 Daratumumab (DARA) Plus…
Shaji Kumar, MD, Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 84…
Shaji Kumar, MD, Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 84…
Dr. Jeffrey Zonder, MD is a Hematology Specialist in Detroit, Michigan, with over 26 years of expertise. In 1995, he…
Dr. Rifkin is a board-certified medical oncologist and hematologist who treats blood malignancies and diseases, both malignant and benign. He…
Dr. Rifkin is a board-certified medical oncologist and hematologist who treats blood malignancies and diseases, both malignant and benign. He…
Mara-Victoria Mateos earned her medical degree from the University of Valladolid in Spain and finished her hematological residency at the…
Mara-Victoria Mateos earned her medical degree from the University of Valladolid in Spain and finished her hematological residency at the…
Daniel Auclair, Ph.D., Chief Scientific Officer, The Multiple Myeloma Research Foundation speaks about Minimal Residual Disease in Myeloma: Application for…
Daniel Auclair, Ph.D., Chief Scientific Officer, The Multiple Myeloma Research Foundation speaks about Minimal Residual Disease in Myeloma: Application for…
Daniel Auclair, Ph.D., Chief Scientific Officer, The Multiple Myeloma Research Foundation speaks about MMRF CureCloud – First At-home Genomic Testing…
Daniel Auclair, Ph.D., Chief Scientific Officer, The Multiple Myeloma Research Foundation speaks about MMRF CureCloud – First At-home Genomic Testing…
Taiga Nishihori, MD from the H. Lee Moffitt Cancer Center & Research Institute speaks about the ASCO 2021 Abstract -…
Taiga Nishihori, MD from the H. Lee Moffitt Cancer Center & Research Institute speaks about the ASCO 2021 Abstract -…
Brian Durie, MD, part of the iStopMM team and chairman of the International Myeloma Foundation speaks about the study -…
Mounzer Agha, MD, is the director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center, and…
Saad Usmani, FACP, MBA, MD from the Department of Hematologic Oncology and Blood Disorders, Atrium Health’s Levine Cancer Institute speaks…
Saad Usmani, FACP, MBA, MD from the Department of Hematologic Oncology and Blood Disorders, Atrium Health’s Levine Cancer Institute speaks…
Dan Sherbenou, MD, Ph.D. from the University of Colorado Medical Campus, Division of Hematology Research, Sherbenou Lab speaks about Older…
Li Du, Ph.D. City of Hope speaks about AACR 2021 Abstract – 1329 – SUMOylation Inhibition Overcomes Dexamethasone Resistance In…
Dawn Marie Stull Medical Science Liaison at Takeda Pharmaceuticals speaks about Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple…
Alessandra Larocca, MD, Ph.D. from the University of Torino, AOU S.Giovanni Battista, TORINO, Italy speaks about Dose/Schedule-Adjusted Rd-R vs Continuous…
Paul G. Richardson, MD from Dana-Farber Cancer Institute speaks about FDA Approves Oncopeptides´ PEPAXTO® (melphalan flufenamide) for Patients with Triple-Class…
Drs. Aggarwal and West welcome Dr. Vincent Rajkumar, Professor of Medicine and multiple myeloma from Mayo Clinic, as they discuss…
Enrique M. Ocio, MD, Ph.D. of the Marqués de Valdecilla University Hospital discusses ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and…
Dr. Irene Ghobrial and Dr. Karen Winkfield give us guidance on a basic action we can all take to help…
Dr. Irene Ghobrial and Dr. Karen Winkfield discuss the ground-breaking study on the disease that will aid in developing new…
Dr. Irene Ghobrial and Dr. Karen Winkfield discuss the markers surrounding the disease and those people most at risk for…
Dr. Irene Ghobrial and Dr. Karen Winkfield describe the symptoms of the disease and how their research study is aiding…
Dr. Irene Ghobrial and Dr. Karen Winkfield talk about the necessity for research to stem the incidence of multiple myeloma
Omar Nadeem, MD from Dana-Farber Cancer Institute speaks about HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory…
Larysa Sanchez, MD from Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute speaks about the ASH 2020 Abstract…
Robert M. Rifkin, MD of the Rocky Mountain Cancer Center speaks about the ASH 2020 Abstract – 3247 DREAMM-7: A…
Robert M. Rifkin, MD of the Rocky Mountain Cancer Center speaks about the ASH 2020 Abstract – 551 The Phase…
Maximilian Merz, MD from Roswell Park Comprehensive Cancer Center speaks about 722 Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma.Introducing:In…
Phillipe Moreau, MD from the University Hospital of Nantes discusses the ASH 2020 abstract – 2316 Isatuximab Plus Carfilzomib and…
Amrita Krishnan, MD, FACP of the City of Hope speaks about the ASH 2020 abstract – 180 Updated Phase 1…
Fredrik Schjesvold, MD, Ph.D. from Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University…
Peter Voorhees, MD – Director of Outreach for Hematologic Malignancies at Atrium Health’s Levine Cancer Institute speaks about ASH 2020…
Jason Valent, MD of the Cleveland Clinic speaks about the ASH 2020 abstract – 729 Safety, Tolerability and Efficacy of…
Thierry Facon, MD from the Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, University of Lille discusses the…
Raymond Comenzo, MD – Director, Transfusion Services, Tufts Medical Center; Director, John C. Davis Myeloma and Amyloid Program, Tufts Medical…
Deepu Madduri, MD – Assistant Professor, Hematology and Medical Oncology of the Mount Sinai Hospital, Mount Sinai Beth Israel discusses…
Alfred L. Garfall, MD, MS – Assistant Professor of Medicine, Perelman School of Medicine discusses ASH 2020 abstract – 180…
Sara Bringhen, MD University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino speaks about ASH 2020…
Meletios A. Dimopoulos, MD – Professor, and Chairman of the Department of Clinical Therapeutics National and Kapodistrian University of Athens…
Ajai Chari, MD, Ph.D. – Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the…
Smith Giri, MD, MHS Institute for Cancer Outcomes and Survivorship, Division of Hematology and Oncology The University of Alabama at…
Kirollos S. Hanna, PharmD, BCPS, BCOP, Oncology Pharmacy Manager, M Health Fairview – Maple Grove; Assistant Professor of Pharmacy, Mayo…
Saad Usmani, M.D., MBA, FACP, Department of Hematologic Oncology and Blood Disorders of Atrium Health Levine Cancer Institute discusses Daratumumabâ€lenalidomideâ€dexamethasone…
Amrita Krishnan, MD, FACP of City of Hope S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct…
Andrzej Jakubowiak, MD, Ph.D. of the University of Chicago Comprehensive Cancer Center speaks on the ASCO 2020 abstract Orvacabtagene autoleucel…
Paul G. Richardson, MD of Dana-Farber Cancer Institute explains the abstract entitled First-in-human phase I study of the novel CELMoD…
Nikhil C. Munshi, MD of Dana-Farber Cancer Institute discusses ASCO20 Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in…
Kristen Hege, MD – Bristol Myers Squibb discusses Phase 1 proof-of-concept data (via an oral presentation) on novel CELMoD CC-92480…
Kristen Hege, MD – Bristol Myers Squibb discusses Phase 1 proof-of-concept data (via an oral presentation) on novel CELMoD CC-92480…
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene…
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene…
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene…
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene…
Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in…
Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in…
Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in…
Sudhir Manda, MD of Arizona Oncology discusses the long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib…
Sudhir Manda, MD of Arizona Oncology discusses the long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib…
Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous…
Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous…
Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous…
Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple…
Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple…
Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple…
Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor…
Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor…
Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the phase I study of teclistamab, a humanized B-cell…
Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj),…
Saad Z. Usmani, M.DÂ @szusmani of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a…
Saad Z. Usmani, M.D of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a…
Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly…
Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly…
Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly…
Earn CME: https://www.naccme.com/program/20-hemcovid-3 In this webcast, Drs. Joseph R. Mikhael and Nina Shah discuss challenges faced by US healthcare practitioners…
Jesus Berdeja, MD of Sarah Cannon Research Institute discusses the BCMA CAR-T therapy JNJ-4528 in pretreated patients with multiple myeloma.…
Jesus Berdeja, MD of Sarah Cannon Research Institute discusses the CAR-T therapy JNJ-4528 in pretreated patients with multiple myeloma. Read…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Ajay Chari…
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’…
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’…
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’…
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’…
Earn CME: https://www.naccme.com/program/19-lm-05 In this webcast from the ‘Multiple Myeloma: Treatment Challenges and Updates’ symposium during the 2019 Lymphoma &…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the alkylating properties in the treatment of relapsed/refractory multple myeloma. ________________ Oncopeptides highlighted…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses the next steps for the ongoing trial once they receive FDA approval and…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides answers where does melphalan flufenamide fit in the mix of RRMM treatment if broad-spectrum…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses results of the HORIZON phase 2 data in RRMM. ________________ Oncopeptides highlighted its…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the combination of the pivotal phase 2 study, HORIZON and phase 3 study,…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the significance of the latest data findings from the O-12-M1 clinical trial recently…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses the 5 clinical trials for the treatment of relapsed/refractory multiple myeloma: O-12-M1, Horizon,…
Peter M. Voorhees, MD @LevineCancer shares the current thinking regarding treatment algorithms in relapsed/refractory multiple myeloma.
Peter M. Voorhees, MD @LevineCancer explains how daratumumab is changing the way multiple myeloma (MM) patients are treated today.
Peter M. Voorhees, MD @LevineCancer summarizes the design and outcomes of the Phase 2 Griffin study in newly diagnosed multiple…
Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, offers opinion on the most promising…
Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, regarding the role of proteasome inhibitors…
Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, explains the role of daratumumab as…
Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer discusses the data investigating iberdomide presented at ASH…
Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer provides opinion on the role of BCMA CAR-T…
Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer considers the Phase 3 ICARIA-MM study investigating isatuximab…
Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer tells us about the design and outcomes of…
Nikhil Munshi, MD, Professor of Medicine, @HarvardHealth @harvardmed @DanaFarber Director of Basic and Correlative Science, discusses if there is an…
Nikhil Munshi, MD, Professor of Medicine, @HarvardHealth @harvardmed @DanaFarber Director of Basic and Correlative Science, tells us about the outcomes…
Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC explains how JNJ-4528 differs from other CAR-T products.
Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC tells us about the outcomes of the CARTITUDE-1 study…
Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC on how CAR-T cell therapy plays a role in…
Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope tells us about the Phase 3 Dreamm-3 study,…
Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope describes the results of the Phase 1 study…
Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope tells us about the outcomes of the CARTITUDE-1…
Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope elaborates on BCMA-directed strategies for multiple myeloma patients.
Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, offers insight of the Phase 3 ICARIA-MM trial investigating…
Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, tells us about the design and outcomes of the…
Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, explains how novel combination treatment options and sequencing strategies…
Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, elaborates on the role of stem cell transplantation in…
James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, offers his insight on the recent data investigating…
James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses the integration of stem cell transplantation into…
Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA differentiates between various anti-CD-38 monoclonal antibodies and…
Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the promising data on multiple myeloma…
Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the role of CAR-T cell therapy…
Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the role of human BCMA CAR-T…
Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive…
Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive…
Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive…
Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive…
Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center,…
Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center,…
Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center,…
Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center,…
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses what’s next in research for the TOUMRALINE-MM4 study. _________…
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses safety concerns regarding the trial. _________ Read here:Â https://www.takeda.com/newsroom/newsreleases/2019/phase-3-trial-of-ninlaro-ixazomib-as-first-line-maintenance-therapy-met-primary-endpoint-in-multiple-myeloma-patients-not-treated-with-stem-cell-transplantation/ Â
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses whether they will be submitting to the FDA or not.
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine answers why ninlaro was compared to a placebo in TOURMALINE-MM4. Dr. Dimopoulous…
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses the design of the TOURMALINE-MM4 study and answers if the trail…
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses the phase 3 trial of ninlaro as first line maintenance therapy…
Ajay K. Nooka, MD of @WinshipAtEmory discusses multiple myeloma disparities.
Peter Voorhees, MD of @LevineCancer discusses the depth of response to dara, lenalidomide, bortezomib, and dexamethasone (RVd) improves over time…
Jesus Berdeja, MD @BerdejaJesus of Sarah Cannon Center for Blood Cancers discusses the phase 1 clinical study of bb21217.
Fredrik Schjesvold, MD of Oslo University College addresses how this affects clinicians and what is next for research.
Fredrik Schjesvold, MD of Oslo University College disucsses the ICARIA-MM study.
Dawn Marie Stull, PharmD of @TakedaOncology discusses closing the efficacy and effectiveness gap: outcomes in relapsed/refractory multiple myeloma (RRMM) patients…
Dawn Marie Stull, PharmD of @TakedaOncology discusses closing the efficacy and effectiveness gap: outcomes in relapsed/refractory multiple myeloma (RRMM) patients…
Nizar Bahlis, MD of University of Calgary discusses patients with newly diagnosed multiple myeloma (MM) ineligible for transplant: updated analysis…
Agne Paner, MD of @RushMedical discusses updated data from the phase 2 HORIZON study. __________ Oncopeptides AB (Nasdaq Stockholm: ONCO)…
Nikhil Munshi of @DanaFarber discusses the phase I study evaluating interleukin-15 (IL-15) receptor agonist, NKTR-255 in MM and NHL.
Dennis Cooper, MD of @RutgersCancer provides detail on his upcoming presentation at ASH about clinical data on REGN5458
Zsuzsanna Devecseri, MD of @SanofiGenzyme @sanofi discusses the pivotal Phase 3 ICARIA-MM trial of isatuximab, an investigational anti-CD38 monoclonal antibody,…
Deepu Madduri, MD @DMadduri of @MountSinaiNYC @IcahnMountSinai discusses the CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy…
Deepu Madduri, MD @DMadduri of @MountSinaiNYC @IcahnMountSinai discusses the CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy…
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session…
– Results Demonstrated Statistically Significant Improvement in Progression-Free Survival – – Data to be Submitted for Presentation at an Upcoming…
Ajai Chari, MD of @MountSinaiNYC answers how the phase 2 PLEIADES study affects treatment and clinicians today. ____________ About the…
Ajai Chari, MD of @MountSinaiNYC explains a common question asked by colleagues regarding the PLEIADES study: how long do you…
Ajai Chari, MD of @MountSinaiNYC discusses the phase 2 PLEIADES study. _________ About the PLEIADES Trial2Â The non-randomized, open-label, parallel assignment…
Shaji Kumar, MD of Mayo Clinic explains how patient volumes associated with longer survival in MM will affect clinicians and…
Shaji Kumar, MD of Mayo Clinic explains a new study that supports higher patient volumes are associated with longer survival…
Peter Voorhees, MD of Levine Cancer Institute addresses phase 2 GRIFFIN study affecting clinicians and treatment today. _______ The Janssen…
Peter Voorhees, MD of Levine Cancer Institute answers questions received from the audience at IMW 2019 regarding the phase 2…
Peter Voorhees, MD of Levine Cancer Institute answers commonly asked questions by colleagues regarding the phase 2 GRIFFIN study: should…
Peter Voorhees, MD of Levine Cancer Institute explains how the phase 2 GRIFFIN study shows a high response rate in…
Ashley T. Freeman, MD of BC Cancer explains how the idea that higher patient volumes are associated with longer survival…
Ashley T. Freeman, MD of BC Cancer explains commonly asked questions by colleagues: why do myeloma patients seem to do…
Ashley T. Freeman, MD of BC Cancer provides insight on a study in JNCCN that supports the idea that higher…
First Phase 3 Study Combining KYPROLIS and DARZALEX, Two Critical Mechanisms of Action in Treatment of Multiple Myeloma  THOUSAND…
New research adds to accumulating evidence of benefit for patients treated at high-volume facilities or by high-volume providers. PLYMOUTH MEETING,…
      Phase 2 GRIFFIN study presented at 17th IMW meeting is the fourth randomized study to investigate the clinical…
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine…
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine…
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the promise of bispecific antibodies in multiple myeloma…
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the different combinations that are available and still…
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains maintenance regimens for multiple myeloma (MM) patients.
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers discusses the outcomes from the ECOD trial in smoldering…